

ABIOMED INC  
Form 8-K  
October 29, 2013

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): October 29, 2013**

**ABIOMED, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware  
(State or other jurisdiction  
of incorporation)**

**001-09585  
(Commission  
File Number)  
22 Cherry Hill Drive  
Danvers, MA 01923**

**04-2743260  
(IRS Employer  
Identification Number)**

Edgar Filing: ABIOMED INC - Form 8-K

**(Address of principal executive offices) (Zip Code)**

**(978) 646-1400**

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On October 29, 2013, we held an investor meeting in San Francisco, California, at the annual Transcatheter Cardiovascular Therapeutics conference ( TCT2013 ). A copy of selected slides used in the presentation at the investor meeting is attached as Exhibit 99.1 to this current report on Form 8-K and incorporated herein by reference. The selected slides provide an update on our current Impella® 2.5 515 Pre-Market Approval (PMA) FDA regulatory filing and our Impella RP RECOVER RIGHT Humanitarian Device Exemption (HDE) clinical trial.

The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Number	Description
99.1	Abiomed Presentation to Investors dated October 29, 2013 Selected Slides

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ABIOMED, Inc.**

By: /s/ Robert L. Bowen  
Robert L. Bowen  
Vice President and Chief Financial  
Officer

Date: October 29, 2013